Personalized Medicine – Products

DNAnexus and Alida Biosciences collaborate to advance RNA epigenomics by hosting AlidaBio's EpiScout™ Analysis Suite on the DNAnexus cloud platform.

Labor Dr. Wisplinghoff, and Genomic Testing Cooperative (GTC), are excited to announce the launch of their collaboration.

This app note highlights a next-generation approach that enhances the depth of data-independent acquisition (DIA) while maintaining the precision of targeted workflows.

Ncardia, announced the launch of Ncyte® Heart in a Box, a breakthrough 3D cardiac microtissue model designed to drive innovation in cardiovascular research and drug discovery.

InSphero, takes a leading role in the recently awarded Chips JU European UNLOOC Project to advance its technology platform and address diversity in drug efficacy and safety testing.

Oxford Nanopore, announced a landmark strategic partnership with the UK Government. This partnership brings together the UK’s world-class scientific organisations Genomics England, UK Biobank and NHS England, alongside Oxford Nanopore.

Thermo Fisher Scientific has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients eligible for treatment with Servier Pharmaceuticals.

iPSC-derived organoid technology drives advances in drug discovery, disease modeling, and personalized medicine. Our cardiac, brain, intestinal, and liver organoids are essential for disease research and therapeutic development.

MOBILion Systems, Inc., announced a next-generation approach for complex sample analysis poised to disrupt the mass spectrometry industry as it delivers unparalleled speed, sensitivity, specificity and quantitative accuracy.

Azenta, Inc. has announced its participation in the FinnGen project, a large-scale research initiative at the forefront of personalized medicine in Finland.